GIST Cancer UK News


Please see the latest news, research and findings below...

New cancer drug Entrectinib (Rozlytrek) approved for Cancer Drug Fund in England

We are very pleased to hear that NICE has approved the Roche drug Entrectinib (Rozlytrek), for use via the Cancer drug fund (CDF) in England by adults and children 12 years and older, who have advanced NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive solid tumours and no satisfactory treatment options. Eligible patients will have access to […]

Continue reading

VOYAGER Phase 3 clinical trial results…

This week Blueprint Pharmaceuticals announced the results of their Voyager trial which compared AYVAKIT™ (avapritinib) with Regorafenib. The trial did not meet the main aim (or endpoint). As a result they are proposing: To continue promoting avapritinib in the United States for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutated GIST, including […]

Continue reading

New Cancer drug Larotrectinib (Vitrakvi) approved for Cancer Drug Fund in England

We are very pleased to announce that NICE has approved the Bayer drug Larotrectinib (Vitrakvi) for use via the Cancer drug fund (CDF) in England for adults and children who have failed other treatment options and whose tumours test positively for the rare NTRK fusion (Neurotrophic Tyrosine Receptor Kinase fusion). Described as an histology agnostic […]

Continue reading

Covid-19

The government is advising that people with cancer should be particularly stringent in following social distancing measures. Some people with cancer are more at risk of becoming seriously ill if they contract the COVID-19 infection. We have very little information currently, and consequently you should rigorously follow the social distancing advice. If you live with […]

Continue reading

Latest poster for GCUK / PAWS-GIST funded research…

Funds raised by GIST Cancer UK / PAWS-GIST Supporters help us to stimulate and fund research projects aimed at improving treatments for GIST patients. The poster below was recently presented at the National Cancer Research Institutes conference. It highlights PAWS-GIST research that has been funded by GCUK’s PAWS-GIST research fund. None of this would be […]

Continue reading